Scientists believe that combining navitoclax with ruxolitinib will help those with myelofibrosis. Within this trial 50 percent the people have navitoclax and ruxolitinib. One other 50 % have ruxolitinib as well as a dummy drug (placebo ). No utilization of any AbbVie trademark, trade name, or trade costume in this https://carli655vgr7.thebindingwiki.com/user